This Month's Profile Groups: Upheaval and Opportunity Reshape The Oncology Market features profiles of Cyterix Pharmaceuticals, Polaris, Tocagen, Tragara Pharmaceuticals and VentiRx Pharmaceuticals. Patient-Centric Devices Promise Cost-Efficient Wound Care features profiles of Reapplix, Spiracur and Wound Solutions. Plus these Start-Ups Across Health Care: Cebix, Jan Medical, Life Recovery Systems, Respira and SeptRx.

Cyterix Pharmaceuticals Inc. thinks it has found a way to safely increase the maximum tolerated dose of gemcitabine, a widely used cancer drug. The prodrugs that Cyterix is developing are meant to be activated by specific variants within a huge family of enzymes all classified as cytochrome P450 enzymes.

Changing dynamics in oncology, from increasing availability of generics to payors' unapologetic cost-consciousness, are influencing companies of all sizes. Recent ch biostart-up financings show support is available to those positioned to deliver value for money. In this issue we profile Cyterix Pharmaceuticals, Polaris Group, Tesaro, Tocagen, Tragara Pharmaceuticals and VentiRx Pharmaceuticals.

Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.